PMID- 37093160
OWN - NLM
STAT- Publisher
LR  - 20230424
IS  - 2378-8763 (Electronic)
IS  - 2378-8763 (Linking)
DP  - 2023 Apr 21
TI  - Chronic Effects of Oral Cannabidiol Delivery on 24-h Ambulatory Blood Pressure in 
      Patients with Hypertension (HYPER-H21-4): A Randomized, Placebo-Controlled, and 
      Crossover Study.
LID - 10.1089/can.2022.0320 [doi]
AB  - Background: Recent data indicate that cannabidiol (CBD), a nonintoxicating 
      constituent of cannabis, is involved in several aspects of cardiovascular 
      regulation, including blood pressure (BP). However, the impact of chronic CBD 
      administration on 24-h BP and vascular health has not been previously examined in 
      patients with hypertension. The primary aim of this randomized, triple-blind, 
      placebo-controlled, and crossover study was to examine the influence of chronic 
      CBD on 24-h ambulatory BP and arterial stiffness in hypertensive patients. 
      Methods: Seventy patients with mild or moderate primary hypertension, who were 
      untreated or receiving standard of care therapy, were randomly assigned to 
      receive either 5 weeks of oral CBD or placebo-matched controls. Following a 
      >2-week washout period, patients were crossed over to alternate therapy. The 
      primary outcome of the study was dynamic in 24-h ambulatory BP and was assessed 
      using two-way repeated measure analysis of variance. Results: Administration of 
      CBD reduced average 24 h mean, systolic, and diastolic BP after 2.5 weeks 
      (-3.22+/-0.90 mmHg [95% confidence interval -1.01 to -5.44 mmHg], -4.76+/-1.24 mmHg 
      [-1.72 to -7.80 mmHg], and -2.25+/-0.80 mmHg [-0.30 to -6.01 mmHg], respectively 
      (all p<0.05); however, these values largely remained stable following the 
      uptitration of CBD dosing. There were no changes in liver enzymes or serious 
      adverse events (AEs). There was no significant difference in pulse wave velocity 
      (groupxfactor interaction: F=1.50, p=0.226) at different time points, regardless 
      of the intervention arm. Conclusions: In conclusion, chronic administration of 
      CBD reduces ambulatory BP in those with untreated and treated hypertension. In 
      addition, lack of serious AEs implies safety and tolerability of the above-noted 
      CBD formulation. ClinicalTrials.gov ID: NCT05346562, Registered April 6th 2022.
FAU - Dujic, Goran
AU  - Dujic G
AD  - Clinical Department of Diagnostic and Interventional Radiology, University 
      Hospital of Split, Split, Croatia.
FAU - Kumric, Marko
AU  - Kumric M
AUID- ORCID: 0000-0002-9696-3359
AD  - Department of Pathophysiology, University of Split School of Medicine, Split, 
      Croatia.
FAU - Vrdoljak, Josip
AU  - Vrdoljak J
AD  - Department of Pathophysiology, University of Split School of Medicine, Split, 
      Croatia.
FAU - Dujic, Zeljko
AU  - Dujic Z
AD  - Department of Integrative Physiology, University of Split School of Medicine, 
      Split, Croatia.
FAU - Bozic, Josko
AU  - Bozic J
AD  - Department of Pathophysiology, University of Split School of Medicine, Split, 
      Croatia.
LA  - eng
SI  - ClinicalTrials.gov/NCT05346562
PT  - Journal Article
DEP - 20230421
PL  - United States
TA  - Cannabis Cannabinoid Res
JT  - Cannabis and cannabinoid research
JID - 101684827
SB  - IM
OTO - NOTNLM
OT  - ambulatory blood pressure
OT  - arterial stiffness
OT  - cannabidiol
OT  - hypertension
OT  - pulse wave velocity
OT  - randomized controlled trial
EDAT- 2023/04/24 12:42
MHDA- 2023/04/24 12:42
CRDT- 2023/04/24 10:43
PHST- 2023/04/24 12:42 [medline]
PHST- 2023/04/24 12:42 [pubmed]
PHST- 2023/04/24 10:43 [entrez]
AID - 10.1089/can.2022.0320 [doi]
PST - aheadofprint
SO  - Cannabis Cannabinoid Res. 2023 Apr 21. doi: 10.1089/can.2022.0320.